EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lp(a) in chronic kidney disease: state of the art and management perspectives

Leonardo Spatola iD, Rosario Maccarrone iD, Matthias Zeiler, Antonio Granata

Journal of Nephrology · 2026

DOI: 10.1093/joneph/aajag084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Leonardo Spatola und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Dialysis, Ospedale Sant' Antonio Abate, AspTrapani, via Cosenza, Erice, TP, Italy. Hauptthemen laut MEDLINE: Lipoprotein(a), Renal Insufficiency, Chronic, Dyslipidemias, Cardiovascular Diseases. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with chronic kidney disease (CKD) exhibit a higher cardiovascular risk compared to the general population, due to CKD itself and its associated metabolic disorders, such as dyslipidemia. While statin-based management is the current gold standard therapy for dyslipidemia in mild to moderate CKD patients, it has a limited effect on lipoproteins, other than low density lipoproteins such as Lp(a). This limitation should be taken into consideration in cardiovascular risk stratification. Furthermore, statin therapy has not shown any beneficial effects in dialysis patients without prior cardiovascular disease, leading to uncertainty regarding the optimal dyslipidemia management in kidney failure (KF) patients. In this context, high serum Lp(a) levels (>105 nmol/L) should be acknowledged as a significant cardiovascular risk factor due to their pro-atherosclerotic and pro-calcific effects. However, selective Lp(a)-lowering therapies are still lacking in current clinical practice, although novel therapies are emerging in promising Phase III randomized trials. This narrative review summarizes the role of Lp(a) in CKD and discusses current state of the art and future therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)Renal Insufficiency, ChronicDyslipidemiasCardiovascular DiseasesHumansHypolipidemic AgentsHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorsRisk FactorsBiomarkers

Stichwörter der Autor:innen

ASOCKDLp(a)cardiovascular riskdyslipidaemiasiRNAs

Substanzen

Lipoprotein(a)Hypolipidemic AgentsLPA protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsBiomarkers

Autor:innen und Institutionen

  • Division of Nephrology and Dialysis, Ospedale Sant' Antonio Abate, AspTrapani, via Cosenza, Erice, TP, Italy.
  • Division of Nephrology and Dialysis, Ospedale Cannizzaro, Via Messina, Catania, CT, Italy.
  • Division of Nephrology and Dialysis, Ospedale "Carlo Urbani", Jesi, AN, Italy.

ORCID-Profile: Leonardo Spatola, Rosario Maccarrone

Zitieren

APA

Spatola, L., Maccarrone, R., Zeiler, M., & Granata, A. (2026). Lp(a) in chronic kidney disease: state of the art and management perspectives. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag084

Vancouver

Spatola L, Maccarrone R, Zeiler M, Granata A. Lp(a) in chronic kidney disease: state of the art and management perspectives. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag084

BibTeX
@article{Spatola2026,
  author = {Spatola, Leonardo and Maccarrone, Rosario and Zeiler, Matthias and Granata, Antonio},
  title = {Lp(a) in chronic kidney disease: state of the art and management perspectives},
  journal = {Journal of Nephrology},
  year = {2026},
  doi = {10.1093/joneph/aajag084}
}
Kostenlos starten →